Market Cap 48.81B
Revenue (ttm) 9.47B
Net Income (ttm) 2.67B
EPS (ttm) N/A
PE Ratio 18.01
Forward PE 16.46
Profit Margin 28.23%
Debt to Equity Ratio 2.71
Volume 4,508,600
Avg Vol 4,495,890
Day's Range N/A - N/A
Shares Out 422.13M
Stochastic %K 66%
Beta 0.95
Analysts Sell
Price Target $151.13

Company Profile

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides,...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 973 822 7000
Address:
10 Sylvan Way, Parsippany, United States
DonCorleone77
DonCorleone77 Mar. 17 at 4:17 PM
$ELAN $ZTS Attached is page 1 of a Stifel analyst report regarding ELAN and ZTS issued yesterday.
0 · Reply
handmedown1
handmedown1 Mar. 11 at 7:34 PM
$ZTS garbage
0 · Reply
Bazzzigar
Bazzzigar Mar. 11 at 4:14 PM
$ZTS HIMS
0 · Reply
TalkMarkets
TalkMarkets Mar. 4 at 2:25 PM
8 Stocks Trading At Their 52-Week Low $BAM $CRM $TRI $UNH $ZTS https://talkmarkets.com/article/8-stocks-trading-at-their-52-week-low-1772634332
0 · Reply
Estimize
Estimize Mar. 2 at 3:03 PM
Wall St is expecting 1.61 EPS for $ZTS Q1 [Reporting 04/30 BMO] http://www.estimize.com/intro/zts?chart=historical&metric_name=eps&utm_cont
0 · Reply
topstockalerts
topstockalerts Mar. 2 at 1:41 PM
Zoetis Inc. agreed to acquire the animal genomics business of Neogen Corporation for $160 million in cash, expanding its capabilities in precision animal health. The acquisition will provide Zoetis with advanced genetic testing technologies and data analytics tools designed to improve the prediction of health outcomes and enable more tailored treatment and breeding decisions for livestock and companion animals. The genomics unit serves customers in more than 120 countries and operates five laboratories across the U.S., Brazil, Australia, China, and the U.K., along with an office in Canada. Zoetis said the transaction is expected to close in the second half of calendar 2026, subject to customary conditions. The company’s shares have risen about 4.2% in 2025. $ZTS $NEOG
0 · Reply
MyChicago
MyChicago Feb. 25 at 6:09 PM
0 · Reply
SW6
SW6 Feb. 18 at 8:59 PM
0 · Reply
Ripera
Ripera Feb. 17 at 2:44 PM
$ZTS holding above 124.15 50DMA with EPS 6.02, I’m long for a trend crawl
0 · Reply
ZacksResearch
ZacksResearch Feb. 12 at 3:53 PM
$ZTS posts a solid Q4 earnings beat — what's driving the gains? Zoetis delivered Q4 adjusted EPS of $1.48, topping the Zacks Consensus Estimate of $1.40, with total revenues up 3% in the reported quarter to $2.39B. Revenues in the International segment increased 8% year over year on a reported basis, driven by strength in companion animal sales. Discover why ZTS is rallying post-earnings 👉 https://www.zacks.com/stock/news/2862520/zoetis-stock-gains-after-q4-earnings-revenues-beat-estimates?cid=sm-stocktwits-2-2862520-body-33308&ADID=SYND_STOCKTWITS_TWEET_2_2862520_BODY_33308
0 · Reply
Latest News on ZTS
Zoetis: The King Of Animal Health On Sale

Mar 13, 2026, 11:51 AM EDT - 4 days ago

Zoetis: The King Of Animal Health On Sale


Zoetis to Participate in Upcoming Investor Conferences

Mar 5, 2026, 8:30 AM EST - 12 days ago

Zoetis to Participate in Upcoming Investor Conferences


Top 15 High-Growth Dividend Stocks For March 2026

Mar 1, 2026, 10:26 PM EST - 16 days ago

Top 15 High-Growth Dividend Stocks For March 2026

ACN BMI CHH DPZ INTU MA MSCI


Zoetis: Why I'm Doubling Down On My Worst 2025 Pick

Feb 16, 2026, 8:15 AM EST - 4 weeks ago

Zoetis: Why I'm Doubling Down On My Worst 2025 Pick


Zoetis Inc. (ZTS) Q4 2025 Earnings Call Transcript

Feb 12, 2026, 12:44 PM EST - 4 weeks ago

Zoetis Inc. (ZTS) Q4 2025 Earnings Call Transcript


Zoetis Reports Fourth Quarter and Full Year 2025 Results

Feb 12, 2026, 7:00 AM EST - 4 weeks ago

Zoetis Reports Fourth Quarter and Full Year 2025 Results


Zoetis Declares Second Quarter 2026 Dividend

Feb 5, 2026, 4:15 PM EST - 5 weeks ago

Zoetis Declares Second Quarter 2026 Dividend


Zoetis: Undervalued And Oversold

Jan 24, 2026, 8:00 AM EST - 7 weeks ago

Zoetis: Undervalued And Oversold


Zoetis: Cheap Valuation And Attractive Product Launch Pipeline

Jan 14, 2026, 8:22 AM EST - 2 months ago

Zoetis: Cheap Valuation And Attractive Product Launch Pipeline


Trade Tracker: Stephanie Link buys mores Zoetis

Dec 23, 2025, 4:04 PM EST - 3 months ago

Trade Tracker: Stephanie Link buys mores Zoetis


Zoetis Osteoarthritis Pain Franchise Needs A Reset: Analyst

Nov 21, 2025, 12:24 PM EST - 4 months ago

Zoetis Osteoarthritis Pain Franchise Needs A Reset: Analyst


Zoetis to Host Innovation Webcast

Nov 19, 2025, 8:30 AM EST - 4 months ago

Zoetis to Host Innovation Webcast


Zoetis: A High-Quality Compounder Now On Sale?

Nov 14, 2025, 11:35 AM EST - 4 months ago

Zoetis: A High-Quality Compounder Now On Sale?


Zoetis Inc. (ZTS) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:16 PM EST - 4 months ago

Zoetis Inc. (ZTS) Q3 2025 Earnings Call Transcript


Zoetis Stock Outlook Clouded By Rising Competitive Pressures

Nov 4, 2025, 1:15 PM EST - 4 months ago

Zoetis Stock Outlook Clouded By Rising Competitive Pressures


Zoetis: No Longer A Growth Stock

Nov 4, 2025, 12:41 PM EST - 4 months ago

Zoetis: No Longer A Growth Stock


DonCorleone77
DonCorleone77 Mar. 17 at 4:17 PM
$ELAN $ZTS Attached is page 1 of a Stifel analyst report regarding ELAN and ZTS issued yesterday.
0 · Reply
handmedown1
handmedown1 Mar. 11 at 7:34 PM
$ZTS garbage
0 · Reply
Bazzzigar
Bazzzigar Mar. 11 at 4:14 PM
$ZTS HIMS
0 · Reply
TalkMarkets
TalkMarkets Mar. 4 at 2:25 PM
8 Stocks Trading At Their 52-Week Low $BAM $CRM $TRI $UNH $ZTS https://talkmarkets.com/article/8-stocks-trading-at-their-52-week-low-1772634332
0 · Reply
Estimize
Estimize Mar. 2 at 3:03 PM
Wall St is expecting 1.61 EPS for $ZTS Q1 [Reporting 04/30 BMO] http://www.estimize.com/intro/zts?chart=historical&metric_name=eps&utm_cont
0 · Reply
topstockalerts
topstockalerts Mar. 2 at 1:41 PM
Zoetis Inc. agreed to acquire the animal genomics business of Neogen Corporation for $160 million in cash, expanding its capabilities in precision animal health. The acquisition will provide Zoetis with advanced genetic testing technologies and data analytics tools designed to improve the prediction of health outcomes and enable more tailored treatment and breeding decisions for livestock and companion animals. The genomics unit serves customers in more than 120 countries and operates five laboratories across the U.S., Brazil, Australia, China, and the U.K., along with an office in Canada. Zoetis said the transaction is expected to close in the second half of calendar 2026, subject to customary conditions. The company’s shares have risen about 4.2% in 2025. $ZTS $NEOG
0 · Reply
MyChicago
MyChicago Feb. 25 at 6:09 PM
0 · Reply
SW6
SW6 Feb. 18 at 8:59 PM
0 · Reply
Ripera
Ripera Feb. 17 at 2:44 PM
$ZTS holding above 124.15 50DMA with EPS 6.02, I’m long for a trend crawl
0 · Reply
ZacksResearch
ZacksResearch Feb. 12 at 3:53 PM
$ZTS posts a solid Q4 earnings beat — what's driving the gains? Zoetis delivered Q4 adjusted EPS of $1.48, topping the Zacks Consensus Estimate of $1.40, with total revenues up 3% in the reported quarter to $2.39B. Revenues in the International segment increased 8% year over year on a reported basis, driven by strength in companion animal sales. Discover why ZTS is rallying post-earnings 👉 https://www.zacks.com/stock/news/2862520/zoetis-stock-gains-after-q4-earnings-revenues-beat-estimates?cid=sm-stocktwits-2-2862520-body-33308&ADID=SYND_STOCKTWITS_TWEET_2_2862520_BODY_33308
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Feb. 12 at 3:36 PM
0 · Reply
ZacksResearch
ZacksResearch Feb. 12 at 2:53 PM
$ZTS just delivered the kind of quarter bulls love Zoetis topped Q4 earnings and revenue estimates, sending the stock higher, as strong international growth and upbeat 2026 guidance helped offset softness in the U.S. That’s resilience with a forward-looking tailwind. Does this momentum have legs into 2026? Get the full breakdown here 👉 https://www.zacks.com/stock/news/2862520/zoetis-stock-gains-after-q4-earnings-revenues-beat-estimates?cid=sm-stocktwits-2-2862520-teaser-33286&ADID=SYND_STOCKTWITS_TWEET_2_2862520_TEASER_33286
0 · Reply
Bogeymakr
Bogeymakr Feb. 12 at 2:18 PM
0 · Reply
Bazzzigar
Bazzzigar Feb. 12 at 2:16 PM
$ZTS as expected
0 · Reply
OpenOutcrier
OpenOutcrier Feb. 12 at 1:32 PM
$ZTS (+2.6% pre) Zoetis: Q4 Earnings Snapshot https://ooc.bz/l/93125
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 12 at 12:11 PM
$ZTS Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $1.38 up 6.98% YoY • Reported revenue of $2.39B up 3.02% YoY • Zoetis provides full year 2026 revenue guidance of $9.83B to $10.03B, with diluted EPS of $6.65 to $6.75 on a reported basis, or $7.00 to $7.10 on an adjusted basis.
0 · Reply
DonCorleone77
DonCorleone77 Feb. 12 at 3:32 AM
$HWM $ZTS $QSR $H $CROX Some notable companies reporting before tomorrow's open, with earnings consensus estimates: - Howmet Aerospace (HWM), consensus 97c - Zoetis (ZTS), consensus $1.40 - Restaurant Brands (QSR), consensus 95c - US Foods (USFD), consensus $1.01 - Hyatt (H), consensus 34c - TransUnion (TRU), consensus $1.03 - Baxter International (BAX), consensus 54c - Crocs (CROX), consensus $1.91 - TripAdvisor (TRIP), consensus 13c
1 · Reply
NorthStarStats
NorthStarStats Feb. 12 at 2:10 AM
For anyone following along, I developed a Python-based statistical scanner to identify stocks with near-term institutional accumulation and upward price momentum. $ZTS (100), $ZBRA (98), $BMRN (97), $UHS (95), $MKTX (95),
0 · Reply
cubie
cubie Feb. 11 at 9:06 PM
earnings Before Bell so Place ur Bets: $NBIS 75 or 95 (100) $ZBRA 220 or 280 $CROX (65) 70 or $95 (100) $ZTS 115 or 142s $BTDR $9 or $13?
0 · Reply
ZacksResearch
ZacksResearch Feb. 9 at 3:55 PM
$ZTS is expected to potentially beat Q4 earnings expectations. With an Earnings ESP of +0.84% and a Zacks Rank #3, Zoetis is anticipated to deliver a strong performance. The company's diversified portfolio, especially in companion animal products like Simparica Trio and Apoquel, is expected to drive growth, despite challenges in certain segments. Discover more about what's fueling this outlook here 👉 https://www.zacks.com/stock/news/2841564/zoetis-gears-up-to-report-q4-earnings-heres-what-to-expect?cid=sm-stocktwits-2-2841564-body-32586&ADID=SYND_STOCKTWITS_TWEET_2_2841564_BODY_32586
0 · Reply
ZacksResearch
ZacksResearch Feb. 9 at 2:55 PM
$ZTS heading into Q4 earnings — beat setup or regional tug-of-war? The company is set up for a Q4 earnings beat, driven by strong international companion animal products sales, even as weaker U.S. demand weighs on overall results. Find out what this means for the stock 👉 https://www.zacks.com/stock/news/2841564/zoetis-gears-up-to-report-q4-earnings-heres-what-to-expect?cid=sm-stocktwits-2-2841564-teaser-32570&ADID=SYND_STOCKTWITS_TWEET_2_2841564_TEASER_32570
0 · Reply